Stage IV lung cancer survivor Lindi Campbell shares what it was like being diagnosed with advanced disease, how a new treatment has helped her live longer, and why she chose to dedicate her work toward ending the stigma around lung cancer.
In this podcast, Dr. Richard L. Schilsky describes ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study and what has been learned since it launched in 2016.
Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for Advanced Cancers of the Stomach and Esophagus: The ASCO Plenary Series
Read about 2 studies from the November 2023 ASCO Plenary Series, which explore emerging treatments for advanced cancers of the stomach and esophagus.
In this podcast, 3 members of the Cancer.Net Editorial Board discuss new research presented at the 2023 ASCO Annual Meeting in non-small cell lung cancer, small cell lung cancer, and mesothelioma.
2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast Cancer, Lymphoma, Multiple Myeloma, and Brain Tumors
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in breast cancer, lymphoma, multiple myeloma, brain tumors, and von Hippel-Lindau syndrome.
Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent Uterine Cancer: The ASCO Plenary Series
Read research from the July 2023 session of the ASCO Plenary Series, which highlights a study evaluating a potential maintenance therapy option for people with advanced or recurrent TP53 wild-type endometrial cancer.
ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and CAR T-cell Therapy Helps Slow or Stop Multiple Myeloma
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung Cancer, Ovarian Cancer, and Rectal Cancer
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer.
ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays Growth of Ovarian Cancer
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer.
ASCO Annual Meeting 2023: Less-Extensive Hysterectomy Is Effective in Early Cervical Cancer and Adding Ribociclib to Hormone Therapy Lowers Risk of Breast Cancer Recurrence
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. This research explores using less extensive surgery for cervical cancer and using targeted therapy to reduce the risk of breast cancer recurrence.